1184918-22-6

Basic information

• Product Name: 2-Bromo-1-(bromomethyl)-3-fluorobenzene
• Synonyms: 2-Bromo-1-(bromomethyl)-3-fluorobenzene;2-Bromo-3-fluorobenzyl bromide;2-Bromo-1-(bromomethyl)-3-fluorobenzene, alpha,2-Dibromo-3-fluorotoluene;2-Bromo-3-fluorobenzyl bromide 97%;2-Bromo-3-fluorobenzylbromide97%;2-Bromo-1-(bromomethyl)
• CAS NO: 1184918-22-6
• Molecular Formula: C₇H₅Br₂F
• Molecular Weight: 267.9210032
• Mol File: 1184918-22-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 246.8±25.0 °C(Predicted)
• Appearance: Off-white/Solid
• Density: 1.923±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2-Bromo-1-(bromomethyl)-3-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(bromomethyl)-3-fluorobenzene(1184918-22-6)
• EPA Substance Registry System: 2-Bromo-1-(bromomethyl)-3-fluorobenzene(1184918-22-6)

Safety Data

• HazardClass: 8
• Hazardous Substances Data: 1184918-22-6(Hazardous Substances Data)

Usage

Uses

It is employed as a intermediate for pharmaceutical.

Upstream product

• 1184915-45-4 (2-bromo-3-fluorophenyl)methanol 
• 59907-13-0 2-bromo-1-fluoro-3-methylbenzene 

Downstream Products

• 1000339-53-6 2-(2-bromo-3-fluorophenyl)acetonitrile 
• 1255209-05-2 3-(2-bromo-3-fluorophenyl)propanoic acid 

Relevant articles and documents

Lithioarene Cycliacylation and Pd-Catalyzed Aminoethylation/Cyclization to Access Electronically Diverse Saturated Isoquinoline Derivatives

We report operationally facile methods for the synthesis of substituted dihydroisoquinolinones and tetrahydroisoquinolines from readily accessible o-bromobenzyl bromides and o-bromobenzaldehydes, respectively. While classical electrophilic aromatic substitution reactions are tailored to the construction of saturated isoquinolines derived from electron-rich precursors, we demonstrate efficient syntheses from electronically diverse substrates to produce cyclized products as single regioisomers.

Spirocyclic tetrahydroquinazolines

The invention discloses spirocyclic tetrahydroquinazolines , and particularly provide compounds represented by Formula I shown in the specification, and pharmaceutically acceptable salts and solvates thereof. In the formula, R3, A, A1, A2, A3, E, E1, E2, L, Q, Z and a structure shown in the specification are as defined in the specification,. The compounds of formula I are KRAS inhibitors and are therefore useful in the treatment of cancer and other diseases.